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Letter to the EditorThe AMPK-Malonyl-CoA-CPT1 Axis
in the Control of Hypothalamic
Neuronal Function—ReplyDear Editor,
We would like to address the com-
ments by Zammit and Arduini about their
alternative perspective on our recently
published paper in Cell Metabolism
(Lo´pez et al., 2008). We consider their
suggestion about FAS downregulation
an interesting and attractive hypothesis,
but we are not that sure it could be directly
implied from our results. If this was indeed
the case, then it would be expected re-
covery of [malonyl-CoA] to normal values
independently of the fasting time. Our
data do not support this, since hypotha-
lamic [malonyl-CoA] is not totally recov-
ered in 48 hr refed rats previously fasted
by 48 hr, despite the fact that fasting-in-
duced hyperphagia is restored to normal
feeding (Lo´pez et al., 2006). In our opinion
it is more likely that the downregulation of
FAS expression observed during fasting
or ghrelin treatment acts as an adaptive
mechanism that prevents excessive re-
duction of [malonyl-CoA] secondary to
fasting-induced inactivation of ACC by
AMPK. Supporting this concept are our
data showing that the reduction in FAS
levels is not further decreased by pro-
longed fasting over a period of 48 hr (Lo´-
pez et al., 2006). This suggests a tightly
controlled low FAS threshold in hypotha-
lamic neurons. Since malonyl-CoA plays
a critical regulatory role in this system by
acting both as a substrate for fatty acid
biosynthesis and an inhibitor of CPT1
(Obici et al., 2003; Wolfgang et al., 2006;
Lo´pez et al., 2008), we hypothesized that
extremely low levels of [malonyl-CoA]176 Cell Metabolism 8, September 3, 2008 ªmay compromise neuronal viability, by
preventing lipid biosynthesis and by al-
lowing potentially harmful neuronal fatty
acid oxidation during fasting, a situation
of low energy surplus.
With respect to the CPT1 effects on
feeding, we showed that ghrelin increases
hypothalamic CPT1 activity. To determine
whether the effect of ghrelin on food in-
take involved the activation of CPT1, we
investigated the effect on ghrelin’s orexi-
genic action of etomoxir (10 mg), an inhib-
itor of CPT1. Using this selected dose, we
were able to show that while etomoxir
rapidly inhibited hypothalamic CPT1 ac-
tivity, short-term feeding (2, 4, and 6 hr)
was not affected; etomoxir exerted its an-
orectic effect 12 hr after administration
(unpublished data). It is likely that by using
a higher dose of etomoxir, we would have
observed a faster anorectic action;
however, the rationale of using the dose
selected was to show that opposite ef-
fects of this drug and ghrelin occurred
through the same downstream pathway.
We assayed [malonyl-CoA] and CPT1
activity from whole hypothalamic samples
and using similar dilutions; thus, an infini-
tesimal dilution of [malonyl-CoA] was
unlikely. Supporting these data, we have
recently obtained new results showing
that under other experimental settings,
our assays show a perfect [malonyl-
CoA]:CPT1 activity correlation (unpublished
data). We agree that our method is not
specific for CPT1c. However, our interest
in CPT1c stemmed from the recent evi-
dence demonstrating that CPT1cKO2008 Elsevier Inc.mice have decreased feeding and body
weight (Wolfgang et al., 2006). We also
have data showing that CPT1a or CPT1b
expression does not change after ghrelin
treatment at any time evaluated (unpub-
lished data). Specific activity assays for
each CPT1 isoform, ideally associated to
laser-capture microdissection of hypo-
thalamic nuclei, will be required to better
characterize the hypothalamic malonyl-
CoA-CPT1 axis.
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